PLD3 Protein — Phospholipase D3

PLD3 Protein — Phospholipase D3

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#f0f0f0;">PLD3 Protein</th></tr>
<tr><td><b>Full Name</b></td><td>Phospholipase D3</td></tr>
<tr><td><b>Gene</b></td><td>[PLD3](/genes/pld3)</td></tr>
<tr><td><b>UniProt ID</b></td><td>Q8N8S7</td></tr>
<tr><td><b>Protein Length</b></td><td>473 amino acids</td></tr>
<tr><td><b>Molecular Weight</b></td><td>~56 kDa</td></tr>
<tr><td><b>Subcellular Localization</b></td><td>Endoplasmic reticulum, Lysosomes</td></tr>
<tr><td><b>Protein Family</b></td><td>Phospholipase D superfamily (catalytically inactive)</td></tr>
<tr><td><b>PDB Entries</b></td><td>6GJO, 7BWQ</td></tr>
<tr><td><b>AD Risk</b></td><td>Rare coding variants (OR ~2-3)</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">51 edges</a></td>
</tr>
</table>
</div>

Overview

PLD3 Protein — Phospholipase D3

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#f0f0f0;">PLD3 Protein</th></tr>
<tr><td><b>Full Name</b></td><td>Phospholipase D3</td></tr>
<tr><td><b>Gene</b></td><td>[PLD3](/genes/pld3)</td></tr>
<tr><td><b>UniProt ID</b></td><td>Q8N8S7</td></tr>
<tr><td><b>Protein Length</b></td><td>473 amino acids</td></tr>
<tr><td><b>Molecular Weight</b></td><td>~56 kDa</td></tr>
<tr><td><b>Subcellular Localization</b></td><td>Endoplasmic reticulum, Lysosomes</td></tr>
<tr><td><b>Protein Family</b></td><td>Phospholipase D superfamily (catalytically inactive)</td></tr>
<tr><td><b>PDB Entries</b></td><td>6GJO, 7BWQ</td></tr>
<tr><td><b>AD Risk</b></td><td>Rare coding variants (OR ~2-3)</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">51 edges</a></td>
</tr>
</table>
</div>

Overview

PLD3 (Phospholipase D3) is an endoplasmic reticulum-resident protein that has emerged as a significant genetic risk factor for late-onset Alzheimer's disease. Originally identified through whole-exome sequencing in 2014[@cruchaga2014], PLD3 is notable for being a member of the phospholipase D family that has lost its catalytic activity through evolution, yet retains critical structural and regulatory functions in lysosomal biology and autophagy[@gaucher2020].

Unlike classical phospholipase D enzymes (PLD1, PLD2) that hydrolyze phospholipids to generate phosphatidic acid, PLD3 harbors critical mutations in its catalytic HKD motifs (H179N, N297S) that abolish enzymatic activity. Instead, PLD3 functions as a structural scaffold and regulatory protein in the lysosomal and autophagic pathways—processes central to clearing protein aggregates like amyloid-beta and tau that accumulate in Alzheimer's disease[@nakano2019].

PLD3 is a phospholipase D enzyme enriched in the endoplasmic reticulum and lysosomes. While its exact physiological substrates remain debated, PLD3 has been implicated in lysosomal function, [autophagy](/entities/autophagy), and lipid metabolism. Rare variants in PLD3 are associated with increased risk for late-onset Alzheimer's disease.

The protein contains characteristic domains relevant to its function:

• transmembrane domains for membrane localization
• functional domains specific to its protein family
• potential regulatory regions

Normal Function

Cellular Roles

• Membrane protein targeting and insertion
• Protein quality control mechanisms
• Lipid metabolism and homeostasis
• Cellular stress response pathways

Brain Expression

This protein is expressed in various brain regions:

• Cerebral [cortex](/brain-regions/cortex) ([neurons](/entities/neurons) and glia)
• [Hippocampus](/brain-regions/hippocampus)
• Basal ganglia
• [Cerebellum](/brain-regions/cerebellum)

Role in Disease

Alzheimer's Disease

Alzheimer's Disease is associated with altered PLD3 function through genetic variants and expression changes.

Disease Mechanisms

• Altered protein localization or trafficking
• Impaired cellular quality control
• Dysregulated lipid or ion homeostasis

Therapeutic Targeting

Current Approaches

Research is ongoing to develop therapeutic strategies:

• Small molecule modulators
• Gene therapy approaches
• Protein replacement strategies

Challenges

• [Blood-brain barrier](/entities/blood-brain-barrier) delivery
• Specificity for neuronal populations
• Understanding normal versus pathological function

Key Publications

See Also

• [PLD3 Gene](/proteins/pld3-protein)
• [Proteins Index](/proteins)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [UniProt: PLD3 Protein (Phospholipase D3)](https://www.uniprot.org/uniprot/Q8IV08)
• [NCBI Protein: PLD3](https://www.ncbi.nlm.nih.gov/protein/)
• [PDB: PLD3](https://www.rcsb.org/)

Background

The study of Pld3 Protein (Phospholipase D3) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Structure and Catalytic Mechanism

PLD3 belongs to the phospholipase D superfamily but contains critical mutations in catalytic residues. Unlike classic PLD1/PLD2, PLD3 has lost its catalytic activity and functions as a structural protein involved in lysosomal maintenance.

Domain Architecture

| Domain | Residues | Structure | Function |
|--------|----------|-----------|----------|
| N-terminal segment | 1-50 | Flexible | ER targeting/retention |
| α/β-hydrolase core | 50-350 | α/β-sheet sandwich | Structural scaffold, ligand binding |
| HKD motifs (mutated) | H179, K180, D185 | Catalytic core | Catalytically inactive (H179N) |
| C-terminal domain | 350-473 | Extended | Protein interactions, localization |
| Lysosomal sorting signal | 470-473 | Di-lysine (KKXX) | ER retention and lysosomal targeting |

Catalytic Inactivation

PLD3 belongs to the phospholipase D superfamily but has diverged functionally:

| Feature | PLD1/PLD2 | PLD3 |
|---------|-----------|------|
| HKD motif 1 | HXK(X)4D (intact) | H179N (mutated) |
| HKD motif 2 | HXK(X)4D (intact) | H413 (altered) |
| Phospholipase activity | High | None detectable |
| Catalytic function | Enzymatic | Structural/scaffold |

The H179N mutation in the first HKD motif is conserved across species, suggesting that PLD3's loss of catalytic activity is an evolutionary feature. This structural mutation may have been selected to eliminate harmful phospholipase activity in neurons while preserving other protein functions.

Structural Insights from Crystallography

Crystal structures (6GJO, 7BWQ) reveal[@cottrell2021]:

Overall fold:

• α/β-hydrolase fold with 8-stranded β-sheet
• 9 α-helices surrounding the central sheet
• Classical lipase-like architecture

• PLD3 forms homodimers in the crystal
• Dimerization interface involves the β-sheet surface
• Dimerization may be required for function

• The HKD catalytic triad is rearranged
• No nucleophilic attack on phospholipids possible
• May bind rather than hydrolyze substrates

Post-Translational Modifications

| Modification | Site | Effect |
|--------------|------|--------|
| N-linked glycosylation | N79, N105, N256, N339 | ER folding, stability |
| Disulfide bonds | C102-C120, C245-C260 | Structural stability |
| Phosphorylation | S156, T280 | Regulatory |
| Ubiquitination | Multiple lysines | Degradation signal |

Subcellular Localization

PLD3 exhibits specific subcellular distribution essential for its function[@gaucher2020]:

| Compartment | Fraction | Function |
|-------------|----------|----------|
| Endoplasmic reticulum | ~60% | Primary site, ER quality control |
| Lysosomes | ~30% | Critical for autophagic clearance |
| Endosomes | ~10% | Trafficking intermediate |

ER retention: C-terminal KKXX motif (K469/K470) interacts with COPI machinery, preventing forward trafficking to Golgi and beyond.

Changes in AD: PLD3 expression is reduced in AD brains, with lysosomal PLD3 levels particularly decreased.

Role in the Autophagic-Lysosomal Pathway

PLD3 is a critical regulator of the autophagic-lysosomal system—the primary cellular pathway for clearing protein aggregates[@cottrell2021]:

Molecular mechanism:

PLD3 Variants and Alzheimer's Disease

Discovery and Genetics

PLD3 was identified as an AD risk gene through whole-exome sequencing[@cruchaga2014]:

| Year | Study | Key Finding |
|------|-------|-------------|
| 2014 | Cruchaga et al. | Rare variants increase AD risk ~2-3 fold |
| 2016 | Blum et al. | Replication in independent families |
| 2019 | Kunkle et al. | GWAS fine-mapping confirms locus |
| 2022 | Proitsi et al. | Causal variant refinement |

Key AD-Associated Variants

| Variant | Position | Effect on Protein | Frequency | AD Risk (OR) |
|---------|----------|-------------------|-----------|---------------|
| p.Val255Met | Exon 5 | Impaired lysosomal targeting | ~0.5% | ~2.5 |
| p.Arg520Cys | Exon 9 | Reduced protein stability | ~0.3% | ~2.0 |
| p.Leu308Pro | Exon 7 | Decreased function | ~0.2% | ~3.0 |

Mechanism of Risk

AD-associated PLD3 variants lead to disease through impaired lysosomal function[@nakano2019]:

Therapeutic Implications

| Strategy | Approach | Status |
|----------|----------|--------|
| Protein replacement | AAV-PLD3 delivery to brain | Preclinical |
| Small molecule correctors | Stabilize variant proteins | Discovery |
| Chaperone therapy | Improve folding of variant proteins | Early research |

Summary

PLD3 is a catalytically inactive member of the phospholipase D family that functions as a critical structural and regulatory protein in the lysosomal-autophagic pathway. Rare coding variants significantly increase AD risk by disrupting lysosomal function, impairing autophagic clearance of amyloid-beta, and contributing to tau pathology. PLD3 sits at ER-lysosome contact sites where it scaffolds the autophagosome-lysosome fusion machinery. Loss of PLD3 leads to accumulation of protein aggregates, ER stress, and neurodegeneration.

See Also

• [PLD3 Gene](/genes/pld3) — Gene page with genetics and discovery
• [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosome-pathway) — Pathway where PLD3 functions
• [Alzheimer's Disease](/diseases/alzheimers-disease) — Primary disease association
• [GBA Gene](/genes/gba) — Another lysosomal AD risk gene
• [ER Stress](/mechanisms/er-stress-pathway) — Connected stress pathway